Cost-effectiveness of human papillomavirus vaccination and screening in Spain

2010 ◽  
Vol 46 (16) ◽  
pp. 2973-2985 ◽  
Author(s):  
Mireia Diaz ◽  
Silvia de Sanjose ◽  
Jesse Ortendahl ◽  
Meredith O’Shea ◽  
Sue J. Goldie ◽  
...  
Keyword(s):  
Human Papillomavirus ◽  
Cost Effectiveness ◽  
Human Papillomavirus Vaccination

The clinical benefit and cost-effectiveness of human papillomavirus vaccination for adult women in the Netherlands

Vaccine ◽  
2011 ◽  
Vol 29 (48) ◽  
pp. 8929-8936 ◽  
Author(s):  
Johannes A. Bogaards ◽  
Veerle M.H. Coupé ◽  
Chris J.L.M. Meijer ◽  
Johannes Berkhof
Keyword(s):  
Human Papillomavirus ◽  
Cost Effectiveness ◽  
The Netherlands ◽  
Clinical Benefit ◽  
Adult Women ◽  
Human Papillomavirus Vaccination

Retraction: Impact and Cost-effectiveness of Human Papillomavirus Vaccination Campaigns

2021 ◽  
Vol 30 (6) ◽  
pp. 1283-1283
Author(s):  
Allison Portnoy ◽  
Nicole G. Campos ◽  
Stephen Sy ◽  
Emily A. Burger ◽  
Jamie Cohen ◽  
...  
Keyword(s):  
Human Papillomavirus ◽  
Cost Effectiveness ◽  
Human Papillomavirus Vaccination ◽  
Vaccination Campaigns

scholarly journals Cost-effectiveness of a bivalent human papillomavirus vaccination program in Japan

Sexual Health ◽  
2015 ◽  
Vol 12 (6) ◽  
pp. 520 ◽  
Author(s):  
Luke B. Connelly ◽  
Ha N. D. Le
Keyword(s):  
Cervical Cancer ◽  
Human Papillomavirus ◽  
Cost Effectiveness ◽  
Screening Program ◽  
Vaccine Coverage ◽  
Precancerous Lesions ◽  
Hpv Vaccination ◽  
Vaccination Program ◽  
Human Papillomavirus Vaccination ◽  
The Cost

Background Human papillomavirus (HPV) vaccines and their widespread adoption have the potential to relieve a large part of the burden of cervical cancer morbidity and mortality, particularly in countries that have low screening rates or, like Japan, lack a cohesive universal screening program. An economic evaluation was conducted to assess the cost-effectiveness of introducing a bivalent HPV vaccination program in Japan from a healthcare perspective. Methods: A Markov model of the natural history of HPV infection that incorporates both vaccination and screening was developed for Japan. The modelled intervention, a bivalent HPV vaccine with a 100% lifetime vaccine efficacy and 80% vaccine coverage, given to a cohort of 12-year-old Japanese girls in conjunction with the current screening program, was compared with screening alone in terms of costs and effectiveness. A discount rate of 5% was applied to both costs and utilities where relevant. Results: Vaccination alongside screening compared with screening alone is associated with an incremental cost-effectiveness ratio (ICER) of US$20 315 per quality-adjusted-life-year gained if 80% coverage is assumed. The ICER at 5% coverage with the vaccine plus screening, compared with screening alone, is US$1158. Conclusion: The cost-effectiveness results suggest that the addition of a HPV vaccination program to Japan’s cervical cancer screening program is highly likely to prove a cost-effective way to reduce the burden of cervical cancer, precancerous lesions and HPV16/18-related diseases.

scholarly journals Cost-effectiveness of Human Papillomavirus Vaccination in the United States

2008 ◽  
Vol 14 (2) ◽  
pp. 244-251 ◽  
Author(s):  
Harrell W. Chesson ◽  
Donatus U. Ekwueme ◽  
Mona Saraiya ◽  
Lauri E. Markowitz
Keyword(s):  
United States ◽  
Human Papillomavirus ◽  
Cost Effectiveness ◽  
The United States ◽  
Human Papillomavirus Vaccination

scholarly journals PIN68 Cost- Effectiveness Analysis of Human Papillomavirus Vaccination Program in Russia

2011 ◽  
Vol 14 (7) ◽  
pp. A277-A278
Author(s):  
V. Omelyanovsky ◽  
M. Avxentyeva ◽  
I. Krysanov ◽  
O. Ivakhnenko ◽  
S. Goryaynov ◽  
...  
Keyword(s):  
Human Papillomavirus ◽  
Cost Effectiveness ◽  
Cost Effectiveness Analysis ◽  
Vaccination Program ◽  
Human Papillomavirus Vaccination ◽  
Effectiveness Analysis
Sign in / Sign up

Export Citation Format

Share Document